Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: Liver Failure, Liver Transplantation, Encephalopathy
Interventions: Near infrared spectroscopy monitoring, Autoregulation monitoring; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatic Failure
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Orlando, Florida • Indianapolis, Indiana

Conditions: Chronic Hepatitis C Infection
Interventions: Fuzheng Huayu, Placebo; Drug
Lead sponsor: Tarek Hassanein; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Coronado, California • Palo Alto, California • Pasadena, California + 5 more

Conditions: Liver Diseases, Liver Failure, Cirrhosis, Liver
Interventions: Commensal Bacteria Strains; Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: End Stage Liver DIsease, Liver Failure
Interventions: VitaSmart™Liver Machine Perfusion System, Static cold storage; Device · Other
Lead sponsor: Bridge to Life Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: San Bernadino, California • San Francisco, California • Stanford, California + 12 more

Conditions: Hepatic Insufficiency
Interventions: telaprevir (VX-950); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Aurora, California • Fresno, California + 28 more

Conditions: Hepatic Encephalopathy, Cirrhosis, Liver
Interventions: FMT, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatic Encephalopathy, Cirrhosis, Liver
Interventions: HepQuant; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: End Stage Liver Disease, Sarcopenia, Liver Cirrhoses
Interventions: Exercise Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Fulminant Hepatic Failure
Interventions: Standard of Care, ELAD®; Other · Device
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 10 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions: Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 2,859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • West Los Angeles, California • Aurora, Colorado

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Encephalopathy, Cirrhosis
Interventions: Microbiota transplant therapy (MTT) capsules, Placebo capsule; Biological · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: West Haven, Connecticut • Dallas, Texas • Richmond, Virginia

Conditions: Gastric Varices
Interventions: Non-selective beta blockers, Retrograde transvenous obliteration; Drug · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Diseases, Hepatic Insufficiency
Interventions: Baricitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions: ProQuad; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Months to 24 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
Interventions: Sacituzumab Govitecan-hziy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more

Conditions: End Stage Liver Disease
Interventions: Pulmonary Rehabilitation Exercise, Home Based Exercise; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions: Observational Protocol; Other
Lead sponsor: European Foundation for Study of Chronic Liver Failure; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3,000 participants
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more

Conditions: End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness, Cirrhosis, Portal Hypertension
Interventions: Nutritional consultation, Physical training program, Behavioral modification therapy; Other · Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 40 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Search by objective public record fields.

Autoregulation Assessment During Liver Transplantation

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

Study of Telaprevir in Subjects With Hepatic Impairment

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Oral Fecal Transplant in Cirrhosis

Angiotensin 2 for AKI After OLT

HepQuant to Predict Hepatic Encephalopathy After TIPS

Exercise Intervention in Liver Transplant Patients

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

Goals of Care Conversations Study

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Pulmonary Rehabilitation in End-Stage Liver Disease

Intensive Models of HCV Care for Injection Drug Users

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

A Physical Activity Program in End-state Liver Disease

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®